Advice
Following a full submission.
Nebivolol (Nebilet®) is not recommended for use within NHS Scotland for the treatment of stable mild and moderate chronic heart failure (CHF) in addition to standard therapies in elderly patients ≥70 years. Nebivolol, added to standard therapy, was associated with improved left ventricular function and a reduction in a composite endpoint combining all cause mortality and cardiovascular hospitalisation rates in elderly patients with chronic heart failure.There is no comparison with other beta-adrenoceptor blockers.
Cost effectiveness relative to other beta-adrenoceptor blockers in common use in chronic heart failure has not been demonstrated.
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- nebivolol tablets 5mg (Nebilet)
- SMC ID:
- 214/05
- Indication:
- Stable mild and moderate chronic heart failure
- Pharmaceutical company
- Menarini Pharmaceuticals UK
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 September 2006